CAS has migrated to this web app on 5/23/21. If you have an active membership on 5/23/21, log in with your email and password. Otherwise, please create a new account.
We will continue to provide comprehensive analysis and reports about therapeutic antibody licensing deals between Chinese biopharma and overseas companies. In this third business report on this topic, we focus on licensing deals closed in 2022.
DetailsEmbed your knowledge on key antibody concepts, applications and strategies, or upskill the entire team, on Informa Connect Life Science’s most popular course
DetailsFourty antibody deals were closed at a total value of ~ $14.7 billion in 2021. Twenty two of them were in-licensing deals; eighteen were out-licensing deals.
DetailsOxford University Press and the Chinese Antibody Society are pleased to announce their new partnership to launch the journal Antibody Therapeutics this spring.
DetailsActivate 1-year, CAS membership for FREE, using your company domain email to register. See if your employer offers free CAS membership. More to come! Hurry up before the quota runs out.
DetailsThe new, completely upgraded COVID antibody tracker is now part of the the CAS OpenData AI hub. Check out the tracker or read our publication.
Details